Cargando…

Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent

BACKGROUND: Despite an ever-improving understanding of the molecular biology of cancer, the treatment of most cancers has not changed dramatically in the past three decades and drugs that do not discriminate between tumor cells and normal tissues remain the mainstays of anticancer therapy. Since Hsp...

Descripción completa

Detalles Bibliográficos
Autores principales: Horibe, Tomohisa, Kohno, Masayuki, Haramoto, Mari, Ohara, Koji, Kawakami, Koji
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032679/
https://www.ncbi.nlm.nih.gov/pubmed/21235734
http://dx.doi.org/10.1186/1479-5876-9-8